IP Library Assignment 063526/0959
Patent Assignment
Reel/Frame 063526/0959

Nunc Pro Tunc Assignment

Recorded: 2023-05-03 Pages: 6
Assignor
CELGENE CAR LLC
Executed: 2023-04-26
Assignee
BRISTOL-MYERS SQUIBB COMPANY
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NEW JERSEY, 08543
Covered Properties (64)
2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors
Patent: 8,450,335 →
Application: 12/492,180 →
Publication: US 2010/0029610
2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors
Patent: 8,338,439 →
Application: 12/648,693 →
Publication: US 2010/0249092
Heterocyclic Compounds and Uses Thereof
Patent: 8,975,249 →
Application: 13/286,061 →
Publication: US 2012/0149687
Heteroaryl Compounds and Uses Thereof
Patent: 9,238,629 →
Application: 13/286,062 →
Publication: US 2012/0149722
Mutant-Selective Egfr Inhibitors and Uses Thereof
Patent: 8,796,255 →
Application: 13/291,706 →
Publication: US 2012/0157426
2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors
Patent: 8,710,222 →
Application: 13/667,396 →
Publication: US 2013/0065899
Substituted 2,4-Diaminopyrimidines as Kinase Inhibitors
Patent: 9,296,737 →
Application: 13/670,937 →
Publication: US 2013/0065879
2,4-Diaminopyrimidines Useful as Kinase Inhibitors
Patent: 8,609,679 →
Application: 13/671,112 →
Publication: US 2013/0165462
Substituted 2,4-Diaminopyrimidines as Kinase Inhibitors
Patent: 9,212,181 →
Application: 13/671,129 →
Publication: US 2013/0072469
Solid Forms of an Epidermal Growth Factor Receptor Kinase Inhibitor
Patent: 9,056,839 →
Application: 13/801,060 →
Publication: US 2013/0267530
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
Patent: 9,108,927 →
Application: 13/801,191 →
Publication: US 2013/0267531
Erk Inhibitors and Uses Thereof
Patent: 9,145,387 →
Application: 14/175,273 →
Publication: US 2014/0228322
Heteroaryl Compounds and Uses Thereof
Patent: 9,321,786 →
Application: 14/212,048 →
Publication: US 2014/0296233
2,4-Disubstituted Pyrimidines as Kinase Inhibitors
Patent: 9,409,921 →
Application: 14/253,903 →
Publication: US 2014/0213574
Mutant-Selective Egfr Inhibitors and Uses Thereof
Patent: 9,409,887 →
Application: 14/448,578 →
Publication: US 2015/0025055
2,4-Disubstituted Pyrimidine Compounds Useful as Kinase Inhibtors
Patent: 9,375,431 →
Application: 14/636,905 →
Publication: US 2015/0246040
Solid Forms of an Epidermal Growth Factor Receptor Kinase Inhibitor
Patent: 9,539,255 →
Application: 14/734,279 →
Publication: US 2016/0022677
MK2 Inhibitors and Uses Thereof
Application: 14/760,697 →
Publication: US 2015/0376208
Erk Inhibitors and Uses Thereof
Patent: 9,561,228 →
Application: 14/768,190 →
Publication: US 2016/0002176
SUBSTITUTED PYRIDO[2,3-d]PYRIMIDINES AS PROTEIN KINASE INHIBITORS
Patent: 9,663,524 →
Application: 14/776,373 →
Publication: US 2016/0046634
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
Patent: 9,540,335 →
Application: 14/822,366 →
Publication: US 2015/0344441
MK2 Inhibitors and Uses Thereof
Patent: 9,458,175 →
Application: 14/856,311 →
Publication: US 2016/0075720
Erk Inhibitors and Uses Thereof
Patent: 9,504,686 →
Application: 14/858,418 →
Publication: US 2016/0082008
Heteroaryl Compounds and Uses Thereof
Patent: 9,765,038 →
Application: 14/996,874 →
Publication: US 2016/0130236
Substituted 2,4-Diaminopyrimidines as Kinase Inhibitors
Patent: 9,987,276 →
Application: 15/080,351 →
Publication: US 2016/0303121
Heteroaryl Compounds and Uses Thereof
Patent: 9,695,132 →
Application: 15/133,755 →
Publication: US 2016/0221966
Heterocyclic Compounds and Uses Thereof
Patent: 9,867,824 →
Application: 15/192,491 →
Publication: US 2017/0027937
2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors
Application: 15/221,421 →
Publication: US 2017/0100397
Mutant-Selective Egfr Inhibitors and Uses Thereof
Patent: 9,868,723 →
Application: 15/223,343 →
Publication: US 2016/0332994
MK2 Inhibitors and Uses Thereof
Patent: 9,790,235 →
Application: 15/280,157 →
Publication: US 2017/0114073
Erk Inhibitors and Uses Thereof
Patent: 9,796,700 →
Application: 15/361,590 →
Publication: US 2017/0137406
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
Application: 15/401,637 →
Publication: US 2017/0217904
Solid Forms of an Epidermal Growth Factor Receptor Kinase Inhibitor
Application: 15/401,663 →
Publication: US 2017/0281623
Erk Inhibitors and Uses Thereof
Patent: 9,980,964 →
Application: 15/422,617 →
Publication: US 2017/0210729
Forms and Compositions of an Erk Inhibitor
Application: 15/502,639 →
Publication: US 2017/0226083
SUBSTITUTED PYRIDO[2,3-d]PYRIMIDINES AS INHIBITORS OF PROTEIN KINASES
Application: 15/604,786 →
Publication: US 2017/0267685
Heteroaryl Compounds and Uses Thereof
Application: 15/635,954 →
Publication: US 2018/0022713
Heteroaryl Compounds and Uses Thereof
Application: 15/706,031 →
Publication: US 2018/0072687
MK2 Inhibitors and Uses Thereof
Application: 15/782,995 →
Heterocyclic Compounds and Uses Thereof
Application: 15/869,635 →
Publication: US 2018/0353508
Substituted 2,4-Diaminopyrimidines as Kinase Inhibitors
Application: 15/996,162 →
Publication: US 2019/0117650
Forms and Compositions of an Erk Inhibitor
Application: 16/009,080 →
Publication: US 2018/0362498
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
Application: 16/015,626 →
Publication: US 2019/0152925
Solid Forms of an Epidermal Growth Factor Receptor Kinase Inhibitor
Application: 16/015,645 →
Publication: US 2019/0151313
2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors
Application: 16/024,514 →
Publication: US 2019/0192512
SUBSTITUTED PYRIDO[2,3-d]PYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES
Application: 16/114,380 →
Publication: US 2019/0218220
MK2 Inhibitors and Uses Thereof
Application: 16/194,577 →
Publication: US 2019/0135835
Heteroaryl Compounds and Uses Thereof
Application: 16/254,838 →
Publication: US 2019/0375719
MK2 Inhibitors and Uses Thereof
Application: 16/375,317 →
Publication: US 2019/0375762
Heteroaryl Compounds Useful as MK2 Inhibitors
Application: 16/494,690 →
Publication: US 2020/0102325
MK2 Inhibitors, Synthesis Thereof, and Intermediates Thereto
Application: 16/494,701 →
Publication: US 2020/0102326
Deuterated Analogs of MK2 Inhibitors and Uses Thereof
Application: 16/494,711 →
Publication: US 2021/0122762
9,10,11,12-Tetrahydro-8H-[1,4]Diazepino[5',6':4,5]Thieno[3,2-F]Quinolin-8-One Compounds and Uses Thereof
Application: 16/494,722 →
Publication: US 2020/0102327
Forms and Compositions of a MK2 Inhibitor
Application: 16/494,725 →
Publication: US 2020/0148701
Heterocyclic Compounds and Uses Thereof
Application: 16/593,253 →
Publication: US 2020/0276194
Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor
Application: 16/797,776 →
Publication: US 2021/0017137
MK2 Inhibitors and Uses Thereof
Application: 16/802,654 →
Publication: US 2021/0053984
2,4-Disubstituted Pyrimidines Useful as Kinase Inhibitors
Application: 16/825,285 →
Forms and Compositions of a MK2 Inhibitor
Application: 17/136,464 →
Publication: US 2021/0198276
MK2 Inhibitors, Synthesis Thereof, and Intermediates Thereto
Application: 17/148,903 →
Publication: US 2021/0139501
Solid Forms of an Epidermal Growth Factor Receptor Kinase Inhibitor
Application: 17/200,019 →
Publication: US 2022/0062280
Heterocyclic Compounds and Uses Thereof
Application: 17/445,539 →
Publication: US 2022/0218704
Heteroaryl Compounds Useful as MK2 Inhibitors
Application: 17/477,649 →
Publication: US 2022/0064183
Methods of Treating a MK2-Mediated Disorder
Application: 17/611,594 →
Publication: US 2022/0251105
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 10, 2009
From: SINGH, JUSWINDER; PETTER, RUSSELL; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: AVILA THERAPEUTICS, INC.
Reel/Frame 023213/0268 →
Assignment of Assignor's Interest Mar 26, 2010
From: SINGH, JUSWINDER; PETTER, RUSSELL; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: AVILA THERAPEUTICS, INC.
Reel/Frame 024145/0455 →
Assignment of Assignor's Interest Dec 20, 2011
From: LEE, KWANGHO; NIU, DEQIANG; BAEVSKY, MATTHEW FRANK
To: AVILA THERAPEUTICS, INC.
Reel/Frame 027417/0952 →
Assignment of Assignor's Interest Dec 20, 2011
From: LEE, KWANGHO; NIU, DEQIANG; PETTER, RUSSELL C.; SINGH, JUSWINDER
To: AVILA THERAPEUTICS, INC.
Reel/Frame 027417/0939 →
Assignment of Assignor's Interest Dec 20, 2011
From: LEE, KWANGHO; NIU, DEQIANG; PETTER, RUSSELL C.; BAEVSKY, MATTHEW FRANK
To: AVILA THERAPEUTICS, INC.
Reel/Frame 027417/0924 →
Change of Name Sep 28, 2012
From: AVILA THERAPEUTICS, INC.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 029058/0066 →
Assignment of Assignor's Interest Jan 29, 2013
From: SINGH, JUSWINDER; PETTER, RUSSELL; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 029715/0560 →
Assignment of Assignor's Interest Feb 1, 2013
From: SINGH, JUSWINDER; PETTER, RUSSELL C.; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 029740/0109 →
Assignment of Assignor's Interest Feb 1, 2013
From: SINGH, JUSWINDER; PETTER, RUSSELL C.; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 029740/0146 →
Assignment of Assignor's Interest Feb 1, 2013
From: SINGH, JUSWINDER; PETTER, RUSSELL C.; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 029740/0259 →
Assignment of Assignor's Interest Jun 14, 2013
From: CLOVIS ONCOLOGY, INC.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 030616/0491 →
Assignment of Assignor's Interest Jun 14, 2013
From: WITOWSKI, STEVEN RICHARD; TESTER, RICHLAND WAYNE; LEE, KWANGHO
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 030616/0792 →
Assignment of Assignor's Interest Jun 14, 2013
From: LAI, MEI
To: CLOVIS ONCOLOGY, INC.
Reel/Frame 030616/0754 →
Assignment of Assignor's Interest Jun 14, 2013
From: LAI, MEI
To: CLOVIS ONCOLOGY, INC.
Reel/Frame 030616/0450 →
Assignment of Assignor's Interest Jun 18, 2013
From: CLOVIS ONCOLOGY, INC.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 030637/0075 →
Assignment of Assignor's Interest Mar 6, 2014
From: HAQ, NADIA; NIU, DEQIANG; PETTER, RUSSELL C.; QIAO, LIXIN
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 032363/0253 →
Assignment of Assignor's Interest May 7, 2014
From: SINGH, JUSWINDER; PETTER, RUSSELL; TESTER, RICHLAND WAYNE; KLUGE, ARTHUR F.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 032840/0233 →
Assignment of Assignor's Interest Oct 10, 2014
From: SINGH, JUSWINDER
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 033927/0162 →
Assignment of Assignor's Interest Oct 10, 2014
From: D'AGOSTINO, LAURA AKULLIAN; SJIN, ROBERT TJIN THAM; NIU, DEQIANG; MCDONALD, JOSEPH JOHN
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 033927/0167 →
Assignment of Assignor's Interest Nov 18, 2014
From: BARRAGUE, MATTHIEU; GROSS, ALEXANDRE; MUNSON, MARK
To: SANOFI
Reel/Frame 034196/0253 →
Assignment of Assignor's Interest Sep 9, 2015
From: CLOVIS ONCOLOGY, INC.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 036522/0091 →
Assignment of Assignor's Interest Sep 9, 2015
From: LAI, MEI
To: CLOVIS ONCOLOGY, INC.
Reel/Frame 036522/0032 →
Assignment of Assignor's Interest Mar 2, 2016
From: LEE, KWANGHO; SINGH, JUSWINDER; NIU, DEQIANG; PETTER, RUSSELL C.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 037873/0470 →
Assignment of Assignor's Interest Apr 12, 2016
From: LEE, KWANGHO; NIU, DEQIANG; BAEVSKY, MATTHEW F.
To: CELGENE AVILOMICS RESEARCH, INC.
Reel/Frame 038249/0775 →
Merger and Change of Name Feb 16, 2017
From: CELGENE AVILOMICS RESEARCH, INC.; CELGENE CAR LLC
To: CELGENE CAR LLC
Reel/Frame 041738/0041 →